Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254046 · ClinicalTrials.gov registry record · Phase 3
TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.
A Phase 3 study, sponsored by Tibotec Pharmaceuticals, Ireland.
- Completed
- Registry status
- Phase 3
- Development phase
- 616
- Enrollment target
NCT00254046 is a Phase 3 study that has completed, run by Tibotec Pharmaceuticals, Ireland. The registered enrollment target is 616 participants.
The verdict
NCT00254046, a Phase 3 study, has completed, sponsored by Tibotec Pharmaceuticals, Ireland.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 616 participants
- Enrollment target
Study Summary
The purpose of this study is research with the goal of evaluating the effect of TMC125 (a non-nucleoside reverse transcriptase inhibitor) on slowing down the growth of the HIV virus. The study will also investigate whether this new medication is well tolerated, and to further confirm that the medication is safe to be used.
Interventions
- DRUG Placebo
- DRUG TMC125
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 616 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00254046
The ClinicalTrials.gov registry entry for NCT00254046 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 616 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tibotec Pharmaceuticals, Ireland, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00254046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00254046 about?
NCT00254046 is a clinical study titled "TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.". The purpose of this study is research with the goal of evaluating the effect of TMC125 (a non-nucleoside reverse transcriptase inhibitor) on slowing down the growth of the HIV virus. The study will also investigate whether this new medication is well tolerated, and to further confirm that the medica...
What is the current status of trial NCT00254046?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 616 participants. The study started on 2005-11. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00254046?
The interventions under investigation include: Placebo (DRUG), TMC125 (DRUG).
Who is sponsoring clinical trial NCT00254046?
This trial is sponsored by Tibotec Pharmaceuticals, Ireland, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.